Erschienen in:
21.04.2020 | Original Paper
Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%
verfasst von:
Yi-Hsing Chen, Raz Gepstein, Lazha Sharief, Hsiao-Jung Tseng, Ruoxin Wei, Xiaozhe Zhang, Sue Lightman, Oren Tomkins-Netzer
Erschienen in:
International Ophthalmology
|
Ausgabe 5/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To investigate the efficacy and safety of 1% rimexolone ophthalmic suspension in children with chronic anterior uveitis under real-life conditions in a tertiary center.
Methods
This is a retrospective longitudinal study. Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after switching to rimexolone for best-corrected visual acuity (BCVA), oral steroid use, number of flares, IOP and anti-glaucoma management.
Results
Twenty-four patients (41 eyes) diagnosed with either anterior uveitis (n = 25, 60.0%) or panuveitis (n = 16, 40%) were enrolled. The mean age was 10.5 years (4–16 years). The number of patients requiring oral prednisolone reduced from 8 patients (32.0%) at baseline to 3 patients (20.0%) at 12 months (P < 0.001). Following baseline, the median number of uveitis flares reduced from 2.0 (inter-quartile range (IQR) 1.0–2.75) to 1.0 (IQR 0.0–1.0) compared to the 12 months before baseline (P < 0.001). The mean IOP reduced from baseline (22.0 ± 7.3 mmHg) to 1 month (18.8 ± 8.7 mmHg, P = 0.01) and remained stable up to 12 months (15.9 ± 5.0 mmHg, P < 0.001). Average BCVA, dose of oral prednisolone and anti-glaucoma treatments did not change compared to the baseline. The development for IOP ≥ 30 mmHg was associated with a known corticosteroid response [odds ratio (OR) 6.8, P = 0.003] and a dose > 7.5 mg/day oral prednisolone (OR 4.4, P = 0.033).
Conclusions
Rimexolone 1% ophthalmic suspension is an effective and safe topical steroid for pediatric anterior uveitis.